TGA greenlights Alzheimer's blood test that sees 20 years ahead

What just happened

The Therapeutic Goods Administration has authorised the pTau217 blood test — developed by Roche Diagnostics Australia in collaboration with NeuRA (Neuroscience Research Australia) — as a new pathway for Alzheimer’s biomarker detection.

The test measures phosphorylated tau 217 (pTau217) in blood. Elevated pTau217 reflects the accumulation of tau tangles and amyloid plaques in the brain that define Alzheimer’s disease at a pathological level — changes that can begin up to 20 years before any memory or cognitive symptoms appear. The TGA authorisation confirms the test has met Australian regulatory standards. Accuracy is on par with PET brain imaging and lumbar-puncture CSF testing — without the radiation exposure, the procedural risk, or the cost.

The test joins two related diagnostics at the Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis — a joint NeuRA–Roche initiative opened last week by Federal Health and Ageing Minister Mark Butler: the earlier-approved pTau181 test and ApoE4 genetic testing.

One critical caveat: the test is currently available only within clinical trials. A clinical assay pathway — enabling use outside of trials — is expected by approximately October 2026. MBS listing has no confirmed timeline.

---

Both-and

Why this matters for the 45-year-old woman in the waiting room

Australia has approximately 400,000 people living with dementia. Alzheimer’s disease accounts for the majority of cases. The average age of diagnosis is in the early 70s — but the pathological changes that produce that diagnosis have been accumulating for 20 years prior.

For a woman in midlife who watched her mother’s cognitive decline begin in her late 60s, the existence of a blood test that can detect Alzheimer’s pathology two decades out is not abstract. It is a question about whether she could know. The appeal of that is understandable: knowing creates time. Time to plan legally and financially. Time to enrol in research. Time to make decisions about career and relationships before those decisions become impossible to make.

General practice will be the first place most of those patients land. Not because GPs will be ordering the test — not yet, that will sit with memory specialists and trial teams — but because the patient will have read this news and want to talk about it with someone they trust.

The clinical complexity GPs need to hold

Three things need to be named clearly.

The test is Alzheimer-specific, not dementia-wide. pTau217 reflects Alzheimer’s pathological hallmarks — tau tangles and amyloid burden. Dementia is a broad syndrome with multiple causes: vascular disease, Lewy body pathology, frontotemporal degeneration, mixed presentations. A negative pTau217 does not exclude dementia. A positive one does not mean all cognitive changes are Alzheimer’s. Dr Stephanie Daly, RACGP Victoria chair, has been explicit on this point: “GPs should do a clinical assessment, exclude other causes of changes in cognition, before doing tests such as these.” That clinical step is not a formality — it is the essential filter before any biomarker test.

The therapeutic gap is still real. Australia does not have an approved disease-modifying treatment for Alzheimer’s disease on the PBS. Lecanemab and donanemab have been approved in the United States for early-stage Alzheimer’s; neither is currently available in Australia via public subsidy. An earlier diagnosis creates a longer window — but without a treatment to offer within that window, the current clinical value sits mainly in patient autonomy, research participation, and the legal and financial planning that dementia eventually makes urgent.

MBS listing determines who can actually access this. Without Medicare funding, the pTau217 test will be accessible primarily to research participants and those who can afford private testing. Australia has a documented history of diagnostic advances being practically available only to those with the resources to navigate a private specialist pathway. This test will follow that pattern unless MBS listing proceeds in a timely way. There is no confirmed timeline.

---

My two cents

A 20-year warning window is only useful if something can be done within it. Right now, for Alzheimer’s disease, what can be done is: plan, participate in research, make early legal and financial decisions, and potentially access disease-modifying trials if and when they become available in Australia.

That is not nothing. For many patients, the ability to plan while cognition is intact — rather than having decisions made for them later by others — is worth a great deal.

But the clinical conversation this test will generate is one that general practice needs to be prepared for: the patient who wants to know but has not thought through what knowing means, and the patient who knows exactly what it means and wants to talk about both sides of that at once. Holding both of those without collapsing them — into false reassurance or unnecessary alarm — is the thing GPs will be asked to do in the consulting room, well before this test reaches MBS listing.

The test is a milestone. The system’s capacity to respond to what the test reveals is still catching up.

Verdict: yes — a genuine advance in Australian Alzheimer’s diagnostics. Not yet clinically available outside trials, and without a PBS-listed treatment to follow a positive result. But the direction is clear, and GPs need to be ready for the conversations this news will start today.

---

Sources cited

1. Burge K. ‘Milestone’ Alzheimer’s diagnosis blood test gets green light. newsGP, 31 July 2026. https://www1.racgp.org.au/newsgp/clinical/milestone-in-alzheimer-s-diagnosis-as-new-blood-te
2. Boadle A. Mark Butler and the Holy Grail (of dementia tests). The Medical Republic, 30 July 2026. https://www.medicalrepublic.com.au/mark-butler-and-the-holy-grail-of-dementia-tests/127796